Assessing a theoretical risk of dolutegravir-induced developmental immunotoxicity in juvenile rats

Toxicological Sciences

Volumn 130, Issue 1, 2012, Pages 70-81

  Rhodes, Melissa ^a   Laffan, Susan ^a   Genell, Caroline ^a   Gower, Jill ^a   Maier, Curtis ^a   Fukushima, Tamio ^b   Nichols, Garrett ^a   Bassiri, Ashlyn Eaton ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Developmental immunotoxicity; Dolutegravir; Integrase inhibitor; Rat

Indexed keywords

CYCLOSPORIN A; DOLUTEGRAVIR; INTEGRASE INHIBITOR; RAG1 PROTEIN; RAG2 PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; DRUG MECHANISM; FEMALE; HEMATOLOGY; HISTOPATHOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPHENOTYPING; IMMUNOTOXICITY; JUVENILE ANIMAL; MALE; NONHUMAN; RAT; RISK ASSESSMENT; T LYMPHOCYTE; TOXICITY TESTING; TOXICOKINETICS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH AND DEVELOPMENT; HEMATOLOGIC TESTS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; LYMPH NODES; MALE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RISK ASSESSMENT; SPLEEN; T-LYMPHOCYTE SUBSETS; THYMUS GLAND; WEIGHT GAIN;

EID: 84867779364     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs220     Document Type: Article

References (32)

1. ClinicalTrials.gov. Immune Responses in Patients Treated With Raltegravir (RAG-1/2). http://www.clinicaltrials.gov/ct2/show/NCT00785967?term=ra ltegravir+and+vaccination&rank=1. Accessed October 28, 2011.
2. ClinicalTrials.gov. Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents. http:// www.clinicaltrials.gov/ct2/show/NCT00485264?term=raltegravir+pediatric &rank=1. Accessed October 28, 2011.
3. Conover, W. J. (1980). Practical Nonparametric Statistics, pp. 230-234. Wiley and Sons, New York, NY.
4. de Zwart, L., Scholten, M., Monbaliu, J. G., Annaert, P. P., Van Houdt, J. M., Van den Wyngaert, I., De Schaepdrijver, L. M., Bailey, G. P., Coogan, T. P., Coussement, W. C., et al. (2008). The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod. Toxicol. 26, 220-230.
5. Dunnett, C. W. (1955). A multiple comparisons procedure comparing several treatments with a control. J. Amer. Stat. Assoc. 55, 1096-1121.
6. Food and Drug Administration (FDA). (2007a). Advisory Committee Briefing Document, Merck Research Laboratories, Raltegravir_ACM_BGPK_1.doc, Version 9.2, Aug 2007, FDA Advisory Committee, Product Information. September 5, 2007.
7. Food and Drug Administration (FDA). (2007b). Center for Drug Evaluation and Research. NDA 22-145 Approval Letter. http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2007/022145_Approv.pdf. Accessed March 23, 2012.
8. Gore, E. R., Gower, J., Kurali, E., Sui, J. L., Bynum, J., Ennulat, D., and Herzyk, D. J. (2004). Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation. Toxicology 197, 23-35.
9. Hollander, M., and Walfe, D. A. (1999). Nonparametric Statistical Methods. Wiley and Sons, New York, NY.
10. Holsapple, M. P., and O'Lone, R. (2012). Juvenile immunotoxicology. Toxicol. Pathol. 40, 248-254.
11. International Conference on Harmonization (ICH). (2006). Immunotoxicity Studies for Human Pharmaceuticals. ICH Guideline S8. U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC.
12. Jeong, H. D., and Teale, J. M. (1988). Comparison of the fetal and adult functional B cell repertoires by analysis of VH gene family expression. J. Exp. Med. 168, 589-603.
13. Khiong, K., Murakami, M., Kitabayashi, C., Ueda, N., Sawa, S., Sakamoto, A., Kotzin, B. L., Rozzo, S. J., Ishihara, K., Verella-Garcia, M., et al. (2007). Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J. Clin. Invest. 117, 1270-1281.
14. Kim, D. R., Dai, Y., Mundy, C. L., Yang, W., and Oettinger, M. A. (1999). Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev. 13, 3070-3080.
15. Littell, R. C., Milliken, G. A., Stroup, W. W., and Wolfinger, R. D. (1996). SAS System for MIXED Models. SAS Institute, Cary, NC. Marrella, V., Poliani, P. L., Casati, A., Rucci, F., Frascoli, L., Gougeon, M. L., Lemercier, B., Bosticardo, M., Ravanini, M., Battaglia, M., et al. (2007). A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J. Clin. Invest. 117, 1260-1269.
16. Melek, M., Jones, J. M., O'Dea, M. H., Pais, G., Burke, T. R., Jr, Pommier, Y., Neamati, N., and Gellert, M. (2002). Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc. Natl. Acad. Sci. U.S.A. 99, 134-137.
17. Miller, R. J., Jr. (1981). Simultaneous Statistical Inference. Springer Verlag, New York, NY.
18. Milliken, G. A., and Johnson, D. E. (1984). Analysis of Messy Data, 1st ed. Van Nostrand Reinhold, New York, NY.
19. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., and Papaioannou, V. E. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877.
20. National Research Council (NRC). (2011). Guide for the Care and Use of Laboratory Animals, 8th ed. The National Academies Press, Washington, DC.
21. Royston, J. P. (1982). An extension of Shapiro and Wilk's W test for normality in large samples. Appl. Stat. 31, 115-124.
22. SAS. (1990a). SAS Procedures Guide, Version 6, 3rd ed. SAS Institute Inc, Cary, NC.
23. SAS. (1990b). SAS/STAT User's Guide, Version 6, Vol. 2, 4th ed. SAS Institute Inc, Cary, NC.
24. Satterthwaite, F. W. (1946). An approximate distribution of estimates of variance components. Biometrics Bull. 2, 110-114.
25. Shapiro, S. S., and Wilk, M. B. (1965). An analysis of variance test for normality (complete samples). Biometrika 52, 591-611.
26. Shinkai, Y., Rathbun, G., Lam, K. P., Oltz, E. M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., and Stall, A. M. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867.
27. Silva-Lima, B., Due Theilade-Thomsen, M., Carleer, J., Vidal, J. M., Tomasi, P., and Saint-Raymond, A. (2010). Juvenile animal studies for the development of paediatric medicines: A description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors. Birth Defects Res. B Dev. Reprod. Toxicol. 89, 467-473.
28. Van Gent, D. C., Mizuuchi, K., and Gellert, M. (1996). Similarities between initiation of V(D)J recombination and retroviral integration. Science 271, 1592-1594.
29. Vicente, A., Varas, A., Acedón, R. S., Jiménez, E., Muñoz, J. J., and Zapata, A. G. (1998). Appearance and maturation of T cell subsets during rat thymus ontogeny. Dev. Immunol. 5, 319-331.
30. Villa, A., Notarangelo, L. D., and Roifman, C. M. (2008). Omenn syndrome: Inflammation in leaky severe combined immunodeficiency. J. Allergy Clin. Immunol. 122, 1082-1086.
31. Yancopoulos, G. D., Malynn, B. A., and Alt, F. W. (1988). Developmentally regulated and strain-specific expression of murine VH gene families. J. Exp. Med. 168, 417-435.
32. Developmentally regulated and strain-specific expression of murine VH gene families